36 - Low-dose TRT reshapes the microenvironment of prostate tumors to potentiate response to immunotherapy (ID 14) - Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting

36 - Low-dose TRT reshapes the microenvironment of prostate tumors to potentiate response to immunotherapy (ID 14)

Oncology: Basic & Translational -> Basic Science (O) 36

36 - Low-dose TRT reshapes the microenvironment of prostate tumors to potentiate response to immunotherapy (ID 14)

Session Name

Center for Therapy Excellence YIA Symposium

Speakers

R. Hernandez

Authors

Presentation Topic

Oncology: Basic & Translational -> Basic Science (O)

Presentation Number

36

Poster Award Finalist

2nd Place

Previous Eposter

35 - FLT-PET to evaluate sequencing of chemotherapies to enhance efficacy of treatment in triple negative breast cancers (ID 15)

Next Eposters

37 - Factors predicting metastatic disease in 68Ga-PSMA-11 PET positive osseous lesions in prostate cancer (ID 1231)

38 - Diagnostic Performance of PSMA-Targeted ¹⁸F-DCFPyL PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the Phase 3, Multicenter CONDOR Study (ID 1227)

39 - Survey by the French Medicine Agency (ANSM) of the practice, result and impact of ⁶⁸Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer with non-contributive ¹⁸F-fluorocholine PET/CT: 1177 examinations (ID 1234)

40 - Preliminary results of a prospective, multicenter trial assessing the impact of ¹⁸F-DCFPyL-PET/CT on the management of patients with recurrent prostate cancer. (ID 1228)

41 - Incidence of local prostate cancer recurrence by 68Ga-PSMA-11 PET/CT is higher after definitive Radiation Therapy than after Radical Prostatectomy: a single center post-hoc retrospective analysis of recurrence patterns of 787 patients. (ID 1233)

42 - Matched-pair comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-rhPSMA-7 PET/CT in patients with primary and biochemical recurrent prostate cancer (ID 1229)

43 - Impact of⁶⁸Ga-PSMA-11 PET on the Management of recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial (ID 1232)

44 - Combined value of PSMA-based 18F-DCFPyL, 18F-FDG and 18F-NaF PET/CT imaging in metastatic prostate cancer patients (ID 1230)

45 - The effect of changes of serum thyrotropin receptor antibody on the outcome of radioactive iodide therapy for Graves’ hyperthyroidism (ID 283)

46 - Visceral fat metabolic activity evaluated by ¹⁸F-FDG PET/CT predicts osteoporosis in healthy postmenopausal Korean women (ID 284)